Breaking News: CADL – Market Insights, Analysis & Latest Updates

CADL

Candel Therapeutics stock drops after pricing public offering

Candel Therapeutics shares fell 30% after a public offering announcement, despite positive phase 3 clinical trial results for CAN-2409 in prostate cancer treatment.

investing.com • 13/12/2024 - 12:46 PM

CADL

Candel shares surge on positive prostate cancer trial

Candel Therapeutics' stock surged 150% after positive phase 3 trial results for CAN-2409, a viral immunotherapy for prostate cancer, showing improved disease-free survival and potential market impact.

investing.com • 11/12/2024 - 12:36 PM

Greed and Fear Index

Note: The data is for reference only.

Greed

Candel Therapeutics stock drops after pricing public offering

Candel shares surge on positive prostate cancer trial

Currency